i-SEP has raised a third round of funds of €2.5 million from its initial shareholders, including the venture capital fund Go Capital Amorçage, a group of business angels, and family offices with the intervention of the Gwenneg crowdfunding platform.
Founded in 2015 in Nantes, France, i-SEP is developing a new intraoperative cell salvage technology (IOCS) which consists in collecting the blood lost by a patient during hemorrhagic surgery in the operating theatre, treating it and then re-infusing it. This common practice benefits more than 4 million people a year in Europe and the United States.
This Medtech startup stands out for its innovative tangential filtration technology, “which preserves platelets, unlike the centrifugation processes used by competitors”. The company is currently finalizing pre-clinical trial on the latest version of its prototype, and is preparing to launch its multi-centre clinical trial (Bordeaux, Rennes, Paris) in the first half of 2020. This new funding will enable i-SEP to implement this clinical trial and to satisfy regulatory requirements to obtain the CE marking at the end of 2020. It will then be able to start the pre-marketing of its system. “This fund raising will help us to complete the development of our technology with the finalization of our third generation prototype”, says Sylvain Picot, Chairman and co-founder of i-SEP with Francis Gadrat and Bertrand Chastenet. At the end of the fund raising, the trio retains a blocking minority.
i-SEP was an award winner at the 2019 Trophées Run Innov show.
Maureen LE MAO